Evaluating the safety and efficacy of baricitinib for the treatment of moderate-to-severe atopic dermatitis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Evaluating the safety and efficacy of baricitinib for the treatment of moderate-to-severe atopic dermatitis

Published:2023-11-29 Issue:18 Volume:24 Page:2153-2159
ISSN:1465-6566
Container-title:Expert Opinion on Pharmacotherapy
language:en
Short-container-title:Expert Opinion on Pharmacotherapy

Author:

Bridgeman Sarah G.¹,Martino Anna K.²³,Strowd Lindsay C.²³

Affiliation:

1. East Tennessee State University James H. Quillen College of Medicine, Johnson City, Tennessee, USA

2. Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA

3. Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14656566.2023.2288698

Reference17 articles.

1. A New Horizon for Atopic Dermatitis Treatments: JAK Inhibitors

2. Major adverse cardiovascular events in patients with atopic dermatitis treated with oral Janus kinase inhibitors: a systematic review and meta-analysis

3. Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phaseIIItrials

4. Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trials

5. Improvement of head and neck symptoms in patients with atopic dermatitis treated with baricitinib based on five Phase III clinical trials

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP